Paolo Dell'oglio1,2, Anne Sophie Valiquette1,3, Sami-Ramzi Leyh-Bannurah1,4, Zhe Tian1,5, Vincent Trudeau1,3, Alessandro Larcher2, Shahrokh F Shariat6, Umberto Capitanio2, Alberto Briganti2, Markus Graefen4, Francesco Montorsi2, Pierre I Karakiewicz1,3. 1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada. 2. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. 3. Department of Urology, University of Montreal Health Centre, Montreal, QC, Canada. 4. Martini-Clinic, Prostate Cancer Centre Hamburg-Eppendorf, Hamburg, Germany. 5. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada. 6. Department of Urology, Medical University of Vienna and General Hospital, Vienna, Austria.
Abstract
INTRODUCTION: The absolute and proportional numbers of elderly patients diagnosed with localized prostate cancer (PCa) are on the rise. We examined treatment trends and reimbursement figures in localized PCa patients aged ≥80 years. METHODS: Between 2000 and 2008, we identified 30 217 localized PCa patients aged ≥80 years in Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Alternative treatment modalities consisted of conservative management (CM), radiation therapy (RT), radical prostatectomy (RP), and primary androgen-deprivation therapy (PADT). For all four modalities, utilization and reimbursements were examined. RESULTS: PADT was the most frequently used treatment modality between 2000 and 2005. CM became the dominant treatment modality from 2006-2008. RP rates were marginal. RT ranked third, and its annual rate increased from 20.77% in 2000 to 29.13% in 2008. Median individual reimbursement of RT was highest and ranged from $29 343 in 2000 to $31 090 in 2008, followed by RP (from $20 560 in 2000 to $19 580 in 2008), PADT (from $18 901 in 2000 to $8000 in 2008), and CM (from $1824 in 2000 to $1938 in 2008). RT contributed to most of the cumulative annual reimbursements from 2003 (49.24%) to 2008 (72.97%). PADT ranked first from 2000 (54.56%) to 2002 (50.49%), but decreased by 19.40% in 2008. CM's contribution increased from 4.42% in 2000 to 6.96% in 2008. RP's share of reimbursements was stable during the study period. CONCLUSIONS: Our results, focusing on localized PCa treatment in patients aged ≥80 years, showed an important increase in rates, median cost, and proportion of cumulative cost related to RT.
INTRODUCTION: The absolute and proportional numbers of elderly patients diagnosed with localized prostate cancer (PCa) are on the rise. We examined treatment trends and reimbursement figures in localized PCa patients aged ≥80 years. METHODS: Between 2000 and 2008, we identified 30 217 localized PCa patients aged ≥80 years in Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Alternative treatment modalities consisted of conservative management (CM), radiation therapy (RT), radical prostatectomy (RP), and primary androgen-deprivation therapy (PADT). For all four modalities, utilization and reimbursements were examined. RESULTS: PADT was the most frequently used treatment modality between 2000 and 2005. CM became the dominant treatment modality from 2006-2008. RP rates were marginal. RT ranked third, and its annual rate increased from 20.77% in 2000 to 29.13% in 2008. Median individual reimbursement of RT was highest and ranged from $29 343 in 2000 to $31 090 in 2008, followed by RP (from $20 560 in 2000 to $19 580 in 2008), PADT (from $18 901 in 2000 to $8000 in 2008), and CM (from $1824 in 2000 to $1938 in 2008). RT contributed to most of the cumulative annual reimbursements from 2003 (49.24%) to 2008 (72.97%). PADT ranked first from 2000 (54.56%) to 2002 (50.49%), but decreased by 19.40% in 2008. CM's contribution increased from 4.42% in 2000 to 6.96% in 2008. RP's share of reimbursements was stable during the study period. CONCLUSIONS: Our results, focusing on localized PCa treatment in patients aged ≥80 years, showed an important increase in rates, median cost, and proportion of cumulative cost related to RT.
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: Shi-Yi Wang; Rong Wang; James B Yu; Xiaomei Ma; Xiao Xu; Simon P Kim; Pamela R Soulos; Avantika Saraf; Cary P Gross Journal: Med Care Date: 2014-08 Impact factor: 2.983
Authors: Claire F Snyder; Kevin D Frick; Amanda L Blackford; Robert J Herbert; Bridget A Neville; Michael A Carducci; Craig C Earle Journal: Cancer Date: 2010-08-23 Impact factor: 6.860
Authors: Jesse D Sammon; Firas Abdollah; Gally Reznor; Daniel Pucheril; Toni K Choueiri; Jim C Hu; Simon P Kim; Marianne Schmid; Akshay Sood; Maxine Sun; Adam S Kibel; Paul L Nguyen; Mani Menon; Quoc-Dien Trinh Journal: Eur Urol Date: 2014-10-29 Impact factor: 20.096
Authors: Paul L Nguyen; Xiangmei Gu; Stuart R Lipsitz; Toni K Choueiri; Wesley W Choi; Yin Lei; Karen E Hoffman; Jim C Hu Journal: J Clin Oncol Date: 2011-03-14 Impact factor: 44.544
Authors: Sameer A Siddiqui; Shomik Sengupta; Jeffrey M Slezak; Eric J Bergstralh; Bradley C Leibovich; Robert P Myers; Horst Zincke; Michael L Blute Journal: J Urol Date: 2006-03 Impact factor: 7.450